Search
CD68-ET3-LV
go.drugbank.com/drugs/DB32864InvestigationalCD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.
COVID19 s-vax loaded autologous dendritic cell vaccine
go.drugbank.com/drugs/DB15814ExperimentalDC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19. … , and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells.
Vevorisertib
go.drugbank.com/drugs/DB21481InvestigationalVevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations … (MK-4440-001)).
Betaprodine
go.drugbank.com/drugs/DB01473ExperimentalIllicitIt has been used in obstetrics, as pre-operative medication, for minor surgical procedures, and for dental procedures. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1067) … An opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration.
Cefacetrile
go.drugbank.com/drugs/DB01414InvestigationalVet approvedA derivative of 7-aminocephalosporanic acid.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseNTx-265
go.drugbank.com/drugs/DB05649InvestigationalIt is also investigating use of the compound for neurodegenerative disorders, such as Huntington’s disease and Alzheimer’s disease. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause
Eritoran
go.drugbank.com/drugs/DB04933InvestigationalEritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Ompenaclid
go.drugbank.com/drugs/DB18819InvestigationalRGX-202 is a recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin).
Synonyms: RGX-202Upanovimab
go.drugbank.com/drugs/DB16505InvestigationalUpanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19
Categories: Experimental Unapproved Treatments for COVID-19NV-18
go.drugbank.com/drugs/DB05886ExperimentalLike phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer … NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer.